Episode
Episode 66. International Myeloma Society 2025 Annual Meeting Updates with Dr. Alfred Garfall: The Bispecific Bonanza
- Podcast
- Blood Cancer Talks
- Published
- Oct 15, 2025
- Duration seconds
- 3136
- Processing state
not_requested- Canonical source
- https://share.transistor.fm/s/d32f56e4
Actions
POST https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-66-international-myeloma-society-2025-annual-meeting-updates-with-dr-alfred-garfall-the-bispecific-bonanza/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-66-international-myeloma-society-2025-annual-meeting-updates-with-dr-alfred-garfall-the-bispecific-bonanza.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
This episode provides comprehensive coverage of key clinical trial updates from the 2025 International Myeloma Society (IMS) Annual Meeting in Toronto, with special focus on bispecific antibodies and novel immunotherapies across the multiple myeloma disease continuum—from smoldering disease through relapsed/refractory settings. Dr. Alfred Garfall provides expert commentary on study design, efficacy, safety considerations, and clinical implications. Topics Covered 1. SMOLDERING MULTIPLE MYELOMA LINKER-SMM1 Phase 2, open-label study of linvoseltamab monotherapy (200 mg) in patients with high-risk smoldering multiple myeloma by 20/2/20 or PETHEMA criteria, with 2-year treatment duration. Discussion Points: Appropriateness of 2-year treatment duration for precursor condition Efficacy and MRD-negative rates Safety considerations in asymptomatic population Patient selection if available today 2. NEWLY DIAGNOSED MULTIPLE MYELOMA MajesTEC-5 Phase 2 trial evaluating three teclistamab-daratumumab-based induction regimens in 49 transplant-eligible NDMM patients, followed by auto-transplant and fixed-duration Tec-Dara maintenance. Discussion Points: Post-induction MRD-negativity rates with Tec-DR and Tec-DVR Grade 3-5 infection rates and infection-related deaths Questionable utility of bortezomib and need for ASCT with 100% MRD-negativity High infection prophylaxis requirements MagnetisMM-6 Phase 1/2 dose-finding study of fixed-dose elranatamab 76 mg Q4W with Dara-Len in 37 transplant-ineligible NDMM patients (median age 75 years). Discussion Points: VGPR or better rates Safety profile including infections and CRS/ICANS Risk of continuous therapy in elderly/frail population LINKER-MM4 Phase 1/2 study of linvoseltamab monotherapy in NDMM with both transplant-eligible and transplant…